Q2 Earnings Forecast for AQST Issued By Leerink Partnrs

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Aquestive Therapeutics in a report issued on Tuesday, May 13th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics’ Q3 2025 earnings at ($0.17) EPS.

A number of other research firms also recently issued reports on AQST. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Thursday. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, Lake Street Capital cut their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $10.67.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $2.38 on Friday. The company has a fifty day simple moving average of $2.76 and a 200 day simple moving average of $3.37. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $5.80. The company has a market cap of $236.38 million, a P/E ratio of -5.29 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics during the fourth quarter valued at about $498,000. Harvey Capital Management Inc. lifted its holdings in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after purchasing an additional 82,958 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Aquestive Therapeutics by 233.6% during the fourth quarter. Renaissance Technologies LLC now owns 95,400 shares of the company’s stock valued at $340,000 after purchasing an additional 66,800 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after purchasing an additional 7,347 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.